These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 23537720)

  • 1. Innovations in coagulation: improved options for treatment of hemophilia A and B.
    Pabinger-Fasching I; Pipe S
    Thromb Res; 2013 Mar; 131 Suppl 2():S1. PubMed ID: 23537720
    [No Abstract]   [Full Text] [Related]  

  • 2. Plasma derivatives: new products and new approaches.
    Sauna ZE; Pandey GS; Jain N; Mahmood I; Kimchi-Sarfaty C; Golding B
    Biologicals; 2012 May; 40(3):191-5. PubMed ID: 22239993
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Substitution therapy of hemorrhagic diseases].
    Haupt H
    Anasthesiol Intensivmed Prax; 1975 Oct; 11(1):137-44. PubMed ID: 1225069
    [No Abstract]   [Full Text] [Related]  

  • 4. Surgery in haemophilic patients with inhibitors.
    Rodriguez-Merchan EC
    Haemophilia; 2004 Sep; 10 Suppl 2():1-2. PubMed ID: 15385039
    [No Abstract]   [Full Text] [Related]  

  • 5. Induction of immune tolerance in hemophiliacs with inhibitors by combined treatment with i.v. IgG, cyclophosphamide and factor VIII or IX.
    Nilsson IM; Berntorp E
    Prog Clin Biol Res; 1990; 324():69-78. PubMed ID: 2106694
    [No Abstract]   [Full Text] [Related]  

  • 6. [Pharmacotherapy of hemophilia with the preparation of Lagochilus inebrians BGE].
    Akopow IE
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1971; 95(1):72-83. PubMed ID: 4104085
    [No Abstract]   [Full Text] [Related]  

  • 7. Estimating and interpreting the pharmacokinetic profiles of individual patients with hemophilia A or B using a population pharmacokinetic approach: communication from the SSC of the ISTH.
    Iorio A; Blanchette V; Blatny J; Collins P; Fischer K; Neufeld E
    J Thromb Haemost; 2017 Dec; 15(12):2461-2465. PubMed ID: 29119666
    [No Abstract]   [Full Text] [Related]  

  • 8. Innovative coagulation factors: albumin fusion technology and recombinant single-chain factor VIII.
    Schulte S
    Thromb Res; 2013 Mar; 131 Suppl 2():S2-6. PubMed ID: 23537723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved coagulation in bleeding disorders by Non-Anticoagulant Sulfated Polysaccharides (NASP).
    Liu T; Scallan CD; Broze GJ; Patarroyo-White S; Pierce GF; Johnson KW
    Thromb Haemost; 2006 Jan; 95(1):68-76. PubMed ID: 16543964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The evolution of recombinant factor replacement for hemophilia.
    Sankar AD; Weyand AC; Pipe SW
    Transfus Apher Sci; 2019 Oct; 58(5):596-600. PubMed ID: 31421983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting TFPI for hemophilia treatment.
    Peterson JA; Maroney SA; Mast AE
    Thromb Res; 2016 May; 141 Suppl 2(Suppl 2):S28-30. PubMed ID: 27207418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of coagulation equilibrium at baseline and during factor VIII and factor IX replacement in haemophiliacs.
    Négrier C; Menart C; Attali O; Petit PY; Lienhart A; Dechavanne M; Ingerslev J
    Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S135-41. PubMed ID: 9819045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Advances in the field of hemophilia therapy].
    Loeliger EA; Veltkamp JJ
    Ned Tijdschr Geneeskd; 1968 Sep; 112(36):1593-5. PubMed ID: 5680135
    [No Abstract]   [Full Text] [Related]  

  • 14. Effects of recombinant human prothrombin on thrombin generation in plasma from patients with hemophilia A and B.
    Hansson KM; Gustafsson D; Skärby T; Frison L; Berntorp E
    J Thromb Haemost; 2015 Jul; 13(7):1293-300. PubMed ID: 25944555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hemophilia and prophylaxis.
    Ljung R
    Pediatr Blood Cancer; 2013; 60 Suppl 1():S23-6. PubMed ID: 23109472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clotting factor concentrate use and occurrence of thrombotic events in patients with hemophilia: A nationwide and 15-year cohort study.
    Tsan YT; Wang JD; Chan WC; Tong KM
    Am J Hematol; 2016 Jun; 91(6):E307-8. PubMed ID: 26972918
    [No Abstract]   [Full Text] [Related]  

  • 17. Monitoring of modified factor VIII and IX products.
    Kitchen S; Gray E; Mertens K
    Haemophilia; 2014 May; 20 Suppl 4():36-42. PubMed ID: 24762273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pioneering designs for recombinant coagulation factors.
    Schulte S
    Thromb Res; 2011; 128 Suppl 1():S9-12. PubMed ID: 22221848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of blood fractions in coagulation disorders.
    Biggs R
    Br J Haematol; 1969 Dec; 17(6):604. PubMed ID: 5357747
    [No Abstract]   [Full Text] [Related]  

  • 20. Hemophilia in Iran.
    Dorgalaleh A; Dadashizadeh G; Bamedi T
    Hematology; 2016 Jun; 21(5):300-10. PubMed ID: 26914731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.